Randomized multicentre trial of gadoxetic acid-enhanced MRIversusconventional MRI or CT in the staging of colorectal cancer liver metastases

• DOI: 10.1002/bjs.9465
• Publication Date: 2014-03-20T18:45:20Z
• Authors: C J Zech; P Korpraphong; A Huppertz; T Denecke; M-J Kim; W Tanomkiat; E Jonas; A Ba-Ssalamah
• Keywords: Gadoxetic acid

Abstract Background This multicentre international randomized trial compared the impact of gadoxetic acid-enhanced magnetic resonance imaging (MRI), MRI with extracellular contrast medium (ECCM-MRI) and contrast-enhanced computed tomography (CE-CT) as a first-line method in patients suspected colorectal cancer liver metastases (CRCLM). Methods Between October 2008 September 2010, CRCLM were to one three modalities. The primary endpoint was proportion for whom further after initial required confident diagnosis. Secondary variables included confidence therapeutic decision, intraoperative deviations from imaging-based surgical plan result additional operative findings, diagnostic efficacy modalities versus pathological extent disease. Results A total 360 enrolled. Efficacy analysed 342 (118, 112 MRI, ECCM-MRI CE-CT respectively procedure). Further 0 118, 19 (17·0 per cent) 44 (39·3 (P < 0·001). Diagnostic high or very 98·3 cent 85·7 65·2 CE-CT. Surgical plans changed during surgery 28, 32 47 respective groups. Conclusion performance better than that modality. No needed group comparison parameters demonstrated superiority MRI. Registration number: NCT00764621(http://clinicaltrials.gov); EudraCT 2008-000583-16 (https://eudract.ema.europa.eu/).